Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00815607 · ClinicalTrials.gov registry record · Phase 1
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
A Phase 1 study, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00815607 is a Phase 1 study that has completed, run by Alaunos Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT00815607, a Phase 1 study, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of an investigational combination drug/immunotherapy for the treatment of Stage III/IV melanoma.
Interventions
- DRUG INXN-1001
- BIOLOGICAL INXN-3001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00815607
The ClinicalTrials.gov registry entry for NCT00815607 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INXN-1001 is the first listed.
NCT00815607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00815607 about?
NCT00815607 is a clinical study titled "Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma". The purpose of this study is to test the safety of an investigational combination drug/immunotherapy for the treatment of Stage III/IV melanoma.
What is the current status of trial NCT00815607?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00815607?
The interventions under investigation include: INXN-1001 (DRUG), INXN-3001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00815607?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.